
|
The European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CMHP) has today recommended the suspension of the Marketing Authorisation for Acomplia because the benefits no longer outweigh the risks. The most recent assessment by the CHMP looked at the available data for the benefits and risks associated with Acomplia (rimonabant), including studies that have been completed since its approval. The analysis showed that there was approximately a doubling of the risk of psychiatric disorders in obese or overweight patients taking Acomplia compared to those taking a placebo (a dummy pill). |
||||||||||||||||||||